These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10348601)

  • 1. [Chronic hepatitis C, autoimmunity and interferon alfa treatment].
    Garcia Buey L; Moreno Otero R
    Rev Esp Enferm Dig; 1999 Mar; 91(3):165-7. PubMed ID: 10348601
    [No Abstract]   [Full Text] [Related]  

  • 2. [Disappearance of serum autoantibodies during treatment with interferon alpha in a patient with chronic hepatitis C].
    Khemissa F; Bauget P; Michel H; Larrey D
    Gastroenterol Clin Biol; 1997; 21(12):998-9. PubMed ID: 9587568
    [No Abstract]   [Full Text] [Related]  

  • 3. Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients.
    Floreani A; Chiaramonte M; Greggio NA; Fabris P; De Lazzari F; Naccarato R; Betterle C
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):71-6. PubMed ID: 9615270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon treatment of children with chronic hepatitis C.
    al-Tawil Y; Nelson C
    Hepatogastroenterology; 1998; 45(20):345-8. PubMed ID: 9638404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune thrombocytopenic purpura and dermatomyositis associated with chronic hepatitis C. A therapeutic dilemma.
    Moccia F
    Ann Ital Med Int; 1998; 13(4):240-3. PubMed ID: 10349207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of autoimmune and extra-hepatic manifestations of HCV infection.
    Lunel F; Cacoub P
    Ann Med Interne (Paris); 2000 Feb; 151(1):58-64. PubMed ID: 10761564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Autoimmune lesions of thyroid as complications of interferon treatment of chronic viral hepatitis].
    Ettinger OA; Nikitin IG; Storozhakov GI
    Ter Arkh; 1999; 71(12):69-72. PubMed ID: 10647210
    [No Abstract]   [Full Text] [Related]  

  • 8. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.
    Pellicano R; Smedile A; Peyre S; Astegiano M; Saracco G; Bonardi R; Rizzetto M
    Minerva Gastroenterol Dietol; 2005 Mar; 51(1):55-61. PubMed ID: 15756146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interferon therapy in chronic viral hepatitis; an autoimmunity dilemma].
    Gutkowski K; Gutkowska D; Bilkiewicz T
    Przegl Lek; 2007; 64(3):148-52. PubMed ID: 17941466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prolonged remission of chronic hepatitis C despite corticoid and immunosuppressive treatment].
    Pariente A; Liversain JM; Briaud M; Texereau P
    Gastroenterol Clin Biol; 1997; 21(8-9):635. PubMed ID: 9587508
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis C therapy: is it really worth it?
    Johanson JF
    Am J Gastroenterol; 1999 May; 94(5):1412-3. PubMed ID: 10235231
    [No Abstract]   [Full Text] [Related]  

  • 12. Mortality rate during interferon alfa-ribavirin combination therapy of chronic hepatitis C.
    Soza A; Hoofnagle JH
    Hepatology; 2003 Jul; 38(1):267. PubMed ID: 12830010
    [No Abstract]   [Full Text] [Related]  

  • 13. Natural leukocyte interferon alfa for the treatment of chronic viral hepatitis in heart transplant recipients.
    Fagiuoli S; Pevere S; Minniti F; Livi U; Caforio AL; Naccarato R; Chiaramonte M
    Transplantation; 2003 Apr; 75(7):982-6. PubMed ID: 12698084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C.
    Shinohara MM; Davis C; Olerud J
    J Drugs Dermatol; 2009 Sep; 8(9):870-2. PubMed ID: 19746680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alfa in the treatment of chronic hepatitis B.
    Zhang FK
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):337-40. PubMed ID: 15313664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host factors and failure of interferon-alpha treatment in hepatitis C virus.
    Gao B; Hong F; Radaeva S
    Hepatology; 2004 Apr; 39(4):880-90. PubMed ID: 15057887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C.
    Gatselis NK; Georgiadou SP; Koukoulis GK; Tassopoulos N; Zachou K; Liaskos C; Hatzakis A; Dalekos GN
    Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1563-73. PubMed ID: 17094775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome to interferon therapy in chronic hepatitis C: insights from mechanistic studies.
    Beard MR
    Antivir Ther; 2004 Oct; 9(5):637-9. PubMed ID: 15535401
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: a wrong track.
    Bastie A; Castera L; Roudot-Thoraval F; Dhumeaux D; Pawlotsky JM
    Hepatology; 2000 Feb; 31(2):547-8. PubMed ID: 10691381
    [No Abstract]   [Full Text] [Related]  

  • 20. Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha.
    Kansu A; Kuloğlu Z; Demirçeken F; Girgin N
    Turk J Gastroenterol; 2004 Dec; 15(4):213-8. PubMed ID: 16249973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.